Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: SLCO1B1

Gene summary for SLCO1B1

Gene summary.

Gene information	Species	Human
	Gene symbol	SLCO1B1
	Gene ID	10599
	Gene name	solute carrier organic anion transporter family member 1B1
	Gene Alias	HBLRR
	Cytomap	12p12.1
	Gene Type	protein-coding
	GO ID	GO:0006725
	UniProtAcc	A0A024RAU7

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
10599	SLCO1B1	NAFLD1	Human	Liver	NAFLD	8.08e-07	6.13e-01	-0.04
10599	SLCO1B1	S41	Human	Liver	Cirrhotic	2.80e-06	8.19e-01	-0.0343
10599	SLCO1B1	S43	Human	Liver	Cirrhotic	7.09e-07	-1.15e-01	-0.0187
10599	SLCO1B1	HCC1_Meng	Human	Liver	HCC	4.97e-92	5.28e-02	0.0246
10599	SLCO1B1	HCC2_Meng	Human	Liver	HCC	4.80e-10	-3.01e-01	0.0107
10599	SLCO1B1	cirrhotic1	Human	Liver	Cirrhotic	6.03e-09	-2.98e-01	0.0202
10599	SLCO1B1	cirrhotic2	Human	Liver	Cirrhotic	4.58e-11	-2.91e-01	0.0201
10599	SLCO1B1	cirrhotic3	Human	Liver	Cirrhotic	1.33e-03	-3.01e-01	0.0215
10599	SLCO1B1	HCC1	Human	Liver	HCC	7.90e-25	4.17e+00	0.5336
10599	SLCO1B1	HCC2	Human	Liver	HCC	7.26e-28	4.84e+00	0.5341
10599	SLCO1B1	Pt13.a	Human	Liver	HCC	1.71e-02	-1.25e-01	0.021
10599	SLCO1B1	Pt13.b	Human	Liver	HCC	7.39e-08	-1.80e-01	0.0251
10599	SLCO1B1	Pt14.b	Human	Liver	HCC	3.55e-04	-1.75e-02	0.018
10599	SLCO1B1	Pt14.d	Human	Liver	HCC	2.82e-04	-2.17e-01	0.0143
10599	SLCO1B1	S016	Human	Liver	HCC	8.11e-03	-3.01e-01	0.2243

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Liver		HCC: Hepatocellular carcinoma
Liver		NAFLD: Non-alcoholic fatty liver disease

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00194396	Liver	NAFLD	aromatic compound catabolic process	102/1882	467/18723	2.29e-14	1.91e-11	102
GO:19013616	Liver	NAFLD	organic cyclic compound catabolic process	105/1882	495/18723	7.04e-14	5.15e-11	105
GO:00442707	Liver	NAFLD	cellular nitrogen compound catabolic process	93/1882	451/18723	1.04e-11	4.34e-09	93
GO:00467006	Liver	NAFLD	heterocycle catabolic process	92/1882	445/18723	1.16e-11	4.52e-09	92
GO:00108765	Liver	NAFLD	lipid localization	79/1882	448/18723	4.75e-07	2.92e-05	79
GO:00068694	Liver	NAFLD	lipid transport	71/1882	398/18723	1.16e-06	5.59e-05	71
GO:0015850	Liver	NAFLD	organic hydroxy compound transport	50/1882	284/18723	6.01e-05	1.32e-03	50
GO:0015721	Liver	NAFLD	bile acid and bile salt transport	10/1882	30/18723	4.67e-04	6.74e-03	10
GO:190136111	Liver	Cirrhotic	organic cyclic compound catabolic process	213/4634	495/18723	1.58e-19	3.67e-17	213
GO:001943911	Liver	Cirrhotic	aromatic compound catabolic process	202/4634	467/18723	6.93e-19	1.28e-16	202
GO:004427011	Liver	Cirrhotic	cellular nitrogen compound catabolic process	195/4634	451/18723	2.99e-18	4.94e-16	195
GO:004670011	Liver	Cirrhotic	heterocycle catabolic process	192/4634	445/18723	7.17e-18	1.12e-15	192
GO:001087611	Liver	Cirrhotic	lipid localization	147/4634	448/18723	6.24e-05	7.12e-04	147
GO:000686911	Liver	Cirrhotic	lipid transport	128/4634	398/18723	4.54e-04	3.69e-03	128
GO:0006787	Liver	Cirrhotic	porphyrin-containing compound catabolic process	8/4634	12/18723	2.59e-03	1.53e-02	8
GO:0033015	Liver	Cirrhotic	tetrapyrrole catabolic process	8/4634	12/18723	2.59e-03	1.53e-02	8
GO:0033013	Liver	Cirrhotic	tetrapyrrole metabolic process	24/4634	59/18723	5.06e-03	2.62e-02	24
GO:0042167	Liver	Cirrhotic	heme catabolic process	7/4634	11/18723	7.11e-03	3.41e-02	7
GO:0046149	Liver	Cirrhotic	pigment catabolic process	7/4634	11/18723	7.11e-03	3.41e-02	7
GO:0006778	Liver	Cirrhotic	porphyrin-containing compound metabolic process	20/4634	49/18723	9.60e-03	4.35e-02	20

Page: 1 2

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa049762	Liver	NAFLD	Bile secretion	20/1043	89/8465	5.08e-03	4.43e-02	3.57e-02	20
hsa0497611	Liver	NAFLD	Bile secretion	20/1043	89/8465	5.08e-03	4.43e-02	3.57e-02	20

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SLCO1B1

SNV

Missense_Mutation

c.473T>C

p.Val158Ala

p.V158A

Q9Y6L6

protein_coding

tolerated(0.17)

benign(0.055)

TCGA-A7-A0D9-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxotere

SLCO1B1

SNV

Missense_Mutation

rs138965366

c.541N>T

p.Arg181Cys

p.R181C

Q9Y6L6

protein_coding

deleterious(0)

probably_damaging(0.991)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

SLCO1B1

SNV

Missense_Mutation

rs748860610

c.1828C>T

p.Arg610Cys

p.R610C

Q9Y6L6

protein_coding

deleterious(0)

probably_damaging(0.954)

TCGA-BH-A0HA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

SLCO1B1

SNV

Missense_Mutation

rs758561937

c.65G>C

p.Arg22Thr

p.R22T

Q9Y6L6

protein_coding

tolerated(0.14)

benign(0.017)

TCGA-D8-A1JA-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

SLCO1B1

SNV

Missense_Mutation

c.1591N>G

p.Thr531Ala

p.T531A

Q9Y6L6

protein_coding

tolerated(0.22)

benign(0.01)

TCGA-D8-A1XL-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicine+cyclophosphamide+tamoxifen

SLCO1B1

SNV

Missense_Mutation

c.1780C>G

p.Leu594Val

p.L594V

Q9Y6L6

protein_coding

tolerated(0.06)

benign(0.344)

TCGA-GM-A2DH-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxol

SLCO1B1

insertion

Frame_Shift_Ins

novel

c.1479_1480insCTCTCTCTTTTTGATATAT

p.Gly494LeufsTer9

p.G494Lfs*9

Q9Y6L6

protein_coding

TCGA-A2-A0CQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

SLCO1B1

insertion

In_Frame_Ins

novel

c.946_947insGGGTCAGCAATG

p.Lys316delinsArgValSerAsnGlu

p.K316delinsRVSNE

Q9Y6L6

protein_coding

TCGA-AR-A0U0-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

SLCO1B1

SNV

Missense_Mutation

novel

c.1706C>T

p.Ser569Leu

p.S569L

Q9Y6L6

protein_coding

deleterious(0)

probably_damaging(0.955)

TCGA-EA-A3HU-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

SLCO1B1

SNV

Missense_Mutation

novel

c.1755T>G

p.Ile585Met

p.I585M

Q9Y6L6

protein_coding

tolerated(0.06)

possibly_damaging(0.841)

TCGA-EA-A5ZE-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
10599	SLCO1B1	TRANSPORTER, DRUGGABLE GENOME		Rosuvastatin	ROSUVASTATIN
10599	SLCO1B1	TRANSPORTER, DRUGGABLE GENOME		135650848	PRAVASTATIN
10599	SLCO1B1	TRANSPORTER, DRUGGABLE GENOME		rocuronium	ROCURONIUM	25279974
10599	SLCO1B1	TRANSPORTER, DRUGGABLE GENOME		ticagrelor	TICAGRELOR	25935875
10599	SLCO1B1	TRANSPORTER, DRUGGABLE GENOME		CLOFIBRATE	CLOFIBRATE	16316932
10599	SLCO1B1	TRANSPORTER, DRUGGABLE GENOME		atrasentan	ATRASENTAN	16513443
10599	SLCO1B1	TRANSPORTER, DRUGGABLE GENOME		rifampin	RIFAMPIN	22562052,21709081,24420746,19374892
10599	SLCO1B1	TRANSPORTER, DRUGGABLE GENOME		GEMFIBROZIL	GEMFIBROZIL	16316932
10599	SLCO1B1	TRANSPORTER, DRUGGABLE GENOME		FENOFIBRATE	FENOFIBRATE	16316932
10599	SLCO1B1	TRANSPORTER, DRUGGABLE GENOME		nateglinide	NATEGLINIDE	18187595

Page: 1 2 3 4 5 6 7 8